Low Testosterone (Hypogonadism): Symptoms, Diagnosis & Treatment Options

PhallusMD — Low Testosterone

Low Testosterone (Hypogonadism): What It Is, How It’s Diagnosed, and What Can Be Done About It

Testosterone is the primary male sex hormone, governing libido, muscle mass, bone density, mood, and energy. When levels fall below the normal range — a condition called hypogonadism — the effects are wide-ranging and often misattributed to aging alone.

19%
of men over 70 have hypogonadism
300
ng/dL — common clinical threshold for Low-T
~1%
decline in testosterone per year after age 30
TRT: well-established, FDA-approved therapies
HCG/Enclomiphene: fertility-preserving alternatives
Lifestyle optimization: meaningful adjunctive benefit

What Is Low Testosterone?

Testosterone is produced primarily in the testes (Leydig cells), with a smaller amount from the adrenal glands. The hypothalamus and pituitary gland regulate production through a feedback loop: the hypothalamus releases GnRH, which signals the pituitary to release LH and FSH, which in turn stimulate the testes to produce testosterone.

When this system breaks down — whether at the level of the testes (primary hypogonadism), the pituitary or hypothalamus (secondary hypogonadism), or both — testosterone levels fall. The distinction matters for treatment: secondary hypogonadism is often reversible with the right intervention, and fertility can frequently be preserved.

Primary vs. Secondary Hypogonadism: Primary hypogonadism means the testes are not producing adequate testosterone despite normal or elevated LH/FSH signals (testicular failure). Secondary means the brain signals are low or absent, so the testes never receive the instruction to produce (pituitary or hypothalamic dysfunction). Many men have mixed or age-related hypogonadism that doesn’t fit neatly into either category.

Testosterone levels naturally decline with age — roughly 1% per year after age 30. But chronological aging is only one factor. Obesity, type 2 diabetes, obstructive sleep apnea, opioid use, and certain medications all suppress testosterone. Many men in their 30s or 40s present with clinically low levels driven by modifiable factors rather than irreversible testicular failure.

The conventional threshold for clinical diagnosis is a total testosterone below 300 ng/dL on two separate morning measurements, combined with symptoms. Some men are symptomatic at levels above 300 ng/dL, particularly when sex hormone-binding globulin (SHBG) is elevated, reducing the fraction of biologically active (free) testosterone.

Symptoms of Low Testosterone

Low testosterone produces a spectrum of symptoms that overlap with other conditions — depression, thyroid disorders, sleep problems, and normal aging among them. No symptom alone is diagnostic, but the combination of several in a man with confirmed low levels points clearly to hypogonadism.

Reduced libido
Diminished sexual interest, reduced frequency of sexual thoughts, decreased initiative — often the first and most noticeable symptom.
Erectile dysfunction
Low T contributes to ED, particularly reduced rigidity and morning erections, though vascular disease is often the primary driver.
Fatigue and low energy
Persistent tiredness that is not fully explained by sleep or activity levels. Men describe feeling “flat” or unmotivated.
Loss of muscle mass
Difficulty building or maintaining muscle despite adequate exercise; increased fat mass particularly in the abdomen.
Mood changes / depression
Irritability, low mood, reduced competitive drive, and cognitive fog are common and frequently underrecognized.
Reduced bone density
Testosterone is essential for bone maintenance. Long-term hypogonadism increases fracture risk and can be asymptomatic until a fracture occurs.
Decreased body hair
Reduced facial and body hair growth; testicular atrophy may also be present, particularly in longstanding or severe cases.
Infertility
Testosterone is essential for spermatogenesis. Men seeking fertility preservation need careful treatment selection — exogenous TRT suppresses sperm production.

How Is Low Testosterone Diagnosed?

Diagnosis requires both laboratory confirmation and clinical symptoms. A single low level on an afternoon blood draw is not sufficient — levels vary throughout the day and must be measured fasting in the morning.

01
Morning blood draw
Total testosterone measured between 7–10 AM when levels peak. Fasting or light fasting preferred. Confirm on two separate occasions if borderline.
02
Full hormone panel
Free testosterone, SHBG, LH, FSH, estradiol, prolactin. LH/FSH distinguish primary from secondary hypogonadism. Elevated prolactin may indicate a pituitary adenoma.
03
Metabolic workup
CBC, comprehensive metabolic panel, PSA (if TRT is being considered), thyroid function, HbA1c. Obesity, insulin resistance, and sleep apnea all suppress testosterone.
04
Symptom assessment
Validated questionnaires (ADAM, AMS) are used to quantify symptom burden. Numbers alone don’t tell the whole story — how the man feels matters.

Free Testosterone Matters: About 60% of testosterone is tightly bound to SHBG and biologically inactive. Free testosterone — the unbound fraction — is what actually reaches tissues. Men with high SHBG can have normal total testosterone but low free testosterone and significant symptoms. Ask your provider about both numbers.

Treatment Options

Treatment selection depends on the cause of hypogonadism, whether fertility is a priority, the man’s preferences for delivery method, and cardiovascular and prostate history. There is no single “right” approach.

First-Line TRT

Testosterone Injections (Cypionate / Enanthate)
IMor subcutaneous; every 1–2 weeks, or more frequently for stable levels

Intramuscular or subcutaneous testosterone cypionate or enanthate is the most widely used TRT formulation and the most cost-effective. Administered every 7–14 days (or more frequently in smaller doses for more stable serum levels), injections produce reliable increases in testosterone with straightforward monitoring.

  • Highly effective; levels confirmed by lab monitoring
  • Peak-and-trough swings can cause energy and mood fluctuations if injected infrequently
  • Weekly self-injection at home is common and well-tolerated
  • Lower cost than gels or pellets; available as generic
  • Suppresses sperm production — not appropriate if fertility is desired
First-Line TRT

Testosterone Gels & Topical Preparations
Dailyapplied to shoulders, upper arms, or inner thigh

Daily topical testosterone (gels, creams, solutions) provides stable, physiologic testosterone levels without peaks and troughs. Applied to skin each morning, they mimic the natural diurnal pattern more closely than weekly injections. Brand names include AndroGel, Testim, Axiron, and Vogelxo; compounded creams are also widely prescribed.

  • Stable daily levels; no injection-related discomfort
  • Transfer risk to partners or children if skin-to-skin contact before gel dries
  • Some men have poor transdermal absorption; levels must be monitored
  • Higher cost than injections; insurance coverage varies
First-Line TRT

Testosterone Pellets (Subcutaneous Implants)
3–6 modosing interval; minor in-office procedure

Testosterone pellets (Testopel and compounded versions) are implanted subcutaneously in the hip or buttock during a brief office procedure. They release testosterone slowly and consistently over 3–6 months, eliminating the need for daily application or regular injections.

  • Excellent compliance — no daily or weekly routine required
  • Stable serum levels without peaks and troughs
  • Minor procedural risks: infection, extrusion (<3%)
  • Dose cannot be adjusted once implanted — requires waiting for pellets to dissolve
  • Not all insurance plans cover pellet therapy
Fertility-Preserving Alternative

HCG (Human Chorionic Gonadotropin)
LHmimetic — stimulates endogenous testosterone production

HCG mimics luteinizing hormone (LH), directly stimulating the Leydig cells in the testes to produce testosterone. Unlike exogenous TRT, HCG maintains testicular size and sperm production, making it the preferred option for men with secondary hypogonadism who want to preserve fertility or simply prefer to maintain endogenous production.

  • Preserves fertility and testicular volume
  • Effective for secondary (central) hypogonadism
  • Subcutaneous injection 2–3 times per week
  • May be used alongside TRT to prevent testicular atrophy
  • Higher cost; not always covered by insurance
  • See the HCG & Enclomiphene page for full detail
Fertility-Preserving Alternative

Enclomiphene / Clomiphene Citrate
Oraldaily tablet; stimulates LH and FSH release

Enclomiphene (and the older racemic mixture clomiphene citrate) are selective estrogen receptor modulators (SERMs) that block estrogen feedback at the hypothalamus, causing the pituitary to release more LH and FSH. This stimulates endogenous testosterone production and preserves spermatogenesis — an advantage for younger men who may want children.

  • Oral dosing (daily tablet) — no injections required
  • Maintains or improves sperm parameters
  • Effective primarily for secondary hypogonadism
  • Enclomiphene (Androxal) is the active isomer with fewer estrogenic side effects than clomiphene
  • Not FDA-approved for male hypogonadism (used off-label)
  • See the HCG & Enclomiphene page for full detail
Important Adjunct

Lifestyle Optimization

For men with borderline-low testosterone driven by modifiable factors, lifestyle changes can meaningfully raise levels before — or alongside — pharmacologic therapy. These are not substitutes for TRT when levels are severely low, but they address root causes that undermine any treatment.

  • Weight loss: Obesity suppresses testosterone via aromatization of T to estrogen in adipose tissue; a 10% reduction in body weight can raise testosterone meaningfully
  • Resistance training: Heavy compound movements acutely and chronically elevate testosterone
  • Sleep optimization: Most testosterone is produced during sleep; untreated sleep apnea dramatically suppresses levels
  • Alcohol reduction: Chronic alcohol use suppresses the HPG axis and directly damages Leydig cells
  • Stress management: Elevated cortisol competes with and suppresses testosterone production

TRT Delivery Methods Compared

Method Frequency Level Stability Fertility Impact Cost Key Consideration
Injections (cypionate/enanthate) Weekly or biweekly Moderate (peaks/troughs) Suppresses sperm Low ($) Most cost-effective; self-injection at home
Daily gels / creams Daily High (stable) Suppresses sperm Moderate ($$) Transfer risk to partners; absorption varies
Pellets Every 3–6 months Very high Suppresses sperm High ($$$) No daily/weekly routine; can’t adjust dose mid-cycle
HCG 2–3x/week Moderate Preserves fertility High ($$$) Best for secondary hypogonadism; maintains testicular size
Enclomiphene Daily oral Moderate Preserves/improves Moderate ($$) Off-label; oral convenience; best for secondary

Monitoring & Safety

TRT requires regular monitoring to ensure levels are therapeutic, to detect side effects early, and to maintain safety over the long term. The 2023 TRAVERSE trial (5,246 men, mean age 57) provided important reassurance: TRT did not increase the rate of major cardiovascular events compared to placebo in men with established or high-risk cardiovascular disease. However, TRT does carry real risks that require surveillance.

What to monitor

  • Testosterone levels — total and free, timed to delivery method (trough before injection, mid-dose for gels)
  • Hematocrit / CBC — TRT stimulates red blood cell production; hematocrit above 54% increases clot risk and requires dose adjustment or phlebotomy
  • Estradiol — testosterone aromatizes to estrogen; elevated estradiol causes gynecomastia, water retention, and mood changes
  • PSA — TRT does not cause prostate cancer, but it may accelerate pre-existing subclinical disease; baseline PSA before starting, monitoring every 6–12 months
  • LH / FSH and semen analysis — if fertility monitoring is relevant
  • Blood pressure, weight, lipids — general cardiovascular health markers

TRT and Cardiovascular Disease (2023 Update): The TRAVERSE trial found no significant increase in MACE (major adverse cardiovascular events) with TRT vs. placebo over 33 months. This largely resolved a decade of uncertainty about cardiovascular safety. However, elevated hematocrit and atrial fibrillation were more common in the TRT group, reinforcing the need for ongoing monitoring.

Get Your Testosterone Evaluated

A simple morning blood draw is all it takes to know where you stand. Find a provider who will interpret your results in the context of how you feel, not just the number.

PhallusMD is an informational resource and does not provide medical advice, diagnosis, or treatment. Speak with a qualified healthcare provider before making any treatment decisions.

Key References

  1. Bhasin S et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
  2. Lincoff AM et al. (TRAVERSE Trial). Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107–117.
  3. Mulhall JP et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423–432.
  4. Harman SM et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86(2):724–731.
  5. Khera M et al. Adult-Onset Hypogonadism. Mayo Clin Proc. 2016;91(7):908–926.